.Nature Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ advanced breast cancer cells as well as active or even steady mind metastases revealed consistent intracranial task and systemic effectiveness of T-DXd.